FY23 consensus $1.59. Alkermes is providing the following updated financial expectations for 2023. These improved expectations reflect the company’s year-to-date financial results through Sept. 30, 2023 and the completion of the separation of the oncology business. The separation is associated with an anticipated reduction in operating expenses of approximately $20M during the last six weeks of 2023, primarily consisting of Research and Development expenses.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALKS:
- Alkermes management to meet with Piper Sandler
- Alkermes: SEC declares Form 10 registration statement filed by Mural effective
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Biotech Alert: Searches spiking for these stocks today
- Alkermes price target lowered to $35 from $37 at Mizuho